Review anchor
Non-receptor tyrosine-protein kinase TNK1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Non-receptor tyrosine-protein kinase TNK1
CHEMBL5334
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Non-receptor tyrosine-protein kinase TNK1 as ChEMBL target CHEMBL5334, mapped to UniProt Q13470. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL5334
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q13470
Non-receptor tyrosine-protein kinase TNK1
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Non-receptor tyrosine-protein kinase TNK1 matters
Non-receptor tyrosine-protein kinase TNK1 is reviewed as Non-receptor tyrosine-protein kinase TNK1 (UniProt Q13470); the current evidence base includes 20 approved drugs, 998 compounds, and 153 assays, with lead potency reaching pChEMBL 9.2.
Protein context
Non-receptor tyrosine-protein kinase TNK1
Non-receptor tyrosine-protein kinase TNK1 Sequence length is 666 aa.
Review this target as Non-receptor tyrosine-protein kinase TNK1, mapped to UniProt Q13470. Sequence length is 666 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt Q13470
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 20 approved drugs, 998 compounds, and 153 assays for this target. The dominant activity type is KD. CHEMBL388978 is the current potency anchor at pChEMBL 9.2.
Use CHEMBL388978 as the tractability anchor when discussing potency (pChEMBL 9.2).
Activity source · ChEMBL 36 via Core Engine
20 approved
pChEMBL 9.2
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Non-receptor tyrosine-protein kinase TNK1 matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q13470, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
998
Total Compounds
153
Total Assays
20
Approved Drugs
IC50: 118.0, KD: 377.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL388978
|
9.2 | IC50 | — |
|
|
No preferred name
CHEMBL5772004
|
8.9 | IC50 | — |
|
|
No preferred name
CHEMBL509032
|
8.7 | Kd | — |
|
|
No preferred name
CHEMBL388978
|
8.6 | Kd | — |
|
|
No preferred name
CHEMBL5756581
|
8.6 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
PACRITINIB
CHEMBL2035187
|
2022 |
|
|
FEDRATINIB
CHEMBL1287853
|
2019 |
|
|
GILTERITINIB
CHEMBL3301622
|
2018 |
|
|
FOSTAMATINIB
CHEMBL2103830
|
2018 |
|
|
BARICITINIB
CHEMBL2105759
|
2017 |
|
|
MIDOSTAURIN
CHEMBL608533
|
2017 |
|
|
NINTEDANIB
CHEMBL502835
|
2014 |
|
|
CERITINIB
CHEMBL2403108
|
2014 |
|
|
DABRAFENIB
CHEMBL2028663
|
2013 |
|
|
AXITINIB
CHEMBL1289926
|
2012 |
|
|
TOFACITINIB
CHEMBL221959
|
2012 |
|
|
TOFACITINIB CITRATE
CHEMBL2103743
|
2012 |
|
|
PONATINIB
CHEMBL1171837
|
2012 |
|
|
CRIZOTINIB
CHEMBL601719
|
2011 |
|
|
PAZOPANIB
CHEMBL477772
|
2009 |
|
|
SUNITINIB
CHEMBL535
|
2006 |
|
|
DASATINIB
CHEMBL5416410
|
2006 |
|
|
ERLOTINIB
CHEMBL553
|
2004 |
Source Header